Sarcoplasmic reticulum function and carnitine palmitoyltransferase‐1 inhibition during progression of heart failure

No abstract is available for this paper.

• Publication year

  2000

• Venue

  British Journal of Pharmacology

• Publication date

  2000-12-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/sj.bjp.0703741PMID 11139455PMCID PMC1572500
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Lounging in a lysosome: the intracellular lifestyle of Coxiella burnetii

  2007cited by this paper
• First clinical trial with etomoxir in patients with chronic congestive heart failure.

  2000cited by this paper
• Mechanisms of altered excitation-contraction coupling in canine tachycardia-induced heart failure, I: experimental studies.

  1999cited by this paper
• Chronic phospholamban-sarcoplasmic reticulum calcium ATPase interaction is the critical calcium cycling defect in dilated cardiomyopathy.

  1999cited by this paper
• Mechanisms of altered excitation-contraction coupling in canine tachycardia-induced heart failure, II: model studies.

  1999cited by this paper
• Insulin resistance in patients with cardiac hypertrophy.

  1999cited by this paper
• Transcriptional modulators targeted at fuel metabolism of hypertrophied heart.

  1999cited by this paper
• Modification of left ventricular hypertrophy by chronic etomoxir treatment

  1999cited by this paper
• Thyroid control of sarcolemmal Na+/Ca2+exchanger and SR Ca2+-ATPase in developing rat heart.

  1998cited by this paper
• Why does the myocardium fail? Insights from basic science.

  1998cited by this paper
• Unloaded heart in vivo replicates fetal gene expression of cardiac hypertrophy

  1998cited by this paper
• Targeted overexpression of the sarcoplasmic reticulum Ca2+-ATPase increases cardiac contractility in transgenic mouse hearts.

  1998cited by this paper
• Cardiac myocyte volume, Ca2+ fluxes, and sarcoplasmic reticulum loading in pressure-overload hypertrophy.

  1997cited by this paper
• Etomoxir improves left ventricular performance of pressure-overloaded rat heart.

  1997cited by this paper
• Blockade of the renin-angiotensin system in cardiac pressure-overload hypertrophy in rats.

  1995cited by this paper
• Dietary medium-chain triglycerides can prevent changes in myosin and SR due to CPT-1 inhibition by etomoxir.

  1995cited by this paper
• Relation between myocardial function and expression of sarcoplasmic reticulum Ca(2+)-ATPase in failing and nonfailing human myocardium.

  1994cited by this paper
• The relative contributions of different intracellular and sarcolemmal systems to relaxation in rat ventricular myocytes.

  1993cited by this paper
• Competition and redistribution among calcium transport systems in rabbit cardiac myocytes.

  1993cited by this paper
• Selective changes in cardiac gene expression during compensated hypertrophy and the transition to cardiac decompensation in rats with chronic aortic banding.

  1993cited by this paper
• Stress-induced alterations in autophagic pathway: relationship to ubiquitin system.

  1992cited by this paper
• Modification of subcellular organelles in pressure‐overloaded heart by etomoxir, a carnitine palmitoyltransferase I inhibitor

  1992cited by this paper
• Switches in cardiac muscle gene expression as a result of pressure and volume overload.

  1992cited by this paper
• Abnormal intracellular modulation of calcium as a major cause of cardiac contractile dysfunction.

  1991cited by this paper
• Remodeling of myocyte dimensions in hypertrophic and atrophic rat hearts.

  1991cited by this paper
• Differences in myosin isoform expression in the subepicardial and subendocardial myocardium during cardiac hypertrophy in the rat.

  1990cited by this paper
• Changing strategies in the management of heart failure.

  1989cited by this paper
• Response of blood pressure and cardiac myosin polymorphism to swimming training in the spontaneously hypertensive rat.

  1982cited by this paper
• Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4

  1970cited by this paper
• Protein measurement with the Folin phenol reagent.

  1951cited by this paper

• Myocardial Metabolism in Heart Failure with Preserved Ejection Fraction

  2024cites this paper
• Cardiac Metabolism, Reprogramming, and Diseases

  2023cites this paper
• Targeting Myocardial Substrate Metabolism in the Failing Heart: Ready for Prime Time?

  2022cites this paper
• Myocardial metabolism in heart failure: Purinergic signalling and other metabolic concepts

  2019cites this paper
• Glucose Metabolism in Cardiac Hypertrophy and Heart Failure

  2019cites this paper
• Dioxygen and Metabolism; Dangerous Liaisons in Cardiac Function and Disease

  2017cites this paper
• Myocardial Energy Substrate Metabolism in Heart Failure : from Pathways to Therapeutic Targets.

  2015cites this paper
• Metabolic modulation by medium chain triglycerides prevents cardiac remodeling in Spontaneously Hypertensive Rat

  2015cites this paper
• Cardiac SERCA2A/B: therapeutic targets for heart failure.

  2014cites this paper
• Fuel Metabolism Plasticity in Pathological Cardiac Hypertrophy and Failure

  2014cites this paper
• Inhibition of Fatty Acid Oxidation to Treat Heart Failure in Patients

  2014cites this paper
• Adrenergic Control of Cardiac Fatty Acid Oxidation in Diabetes

  2014cites this paper
• Targeting mitochondrial oxidative metabolism as an approach to treat heart failure.

  2013cites this paper
• Mechanisms involved in the differential reduction of omega-3 and omega-6 highly unsaturated fatty acids by structural heart disease resulting in "HUFA deficiency".

  2012cites this paper
• Decreased cardiac SERCA2 expression, SR Ca uptake, and contractile function in hypothyroidism are attenuated in SERCA2 overexpressing transgenic rats.

  2011cites this paper
• Glucose metabolism and cardiac hypertrophy.

  2011cites this paper
• attenuated in SERCA2 overexpressing transgenic rats and contractile function in hypothyroidism are Decreased cardiac SERCA2 expression, SR Ca uptake,

  2011cites this paper
• Optimization of Cardiac Metabolism in Heart Failure

  2011cites this paper
• Targeting fatty acid and carbohydrate oxidation--a novel therapeutic intervention in the ischemic and failing heart.

  2011cites this paper
• Molecular Changes in Fatty Acid Oxidation in the Failing Heart

  2011cites this paper
• Parallel effects of β-adrenoceptor blockade on cardiac function and fatty acid oxidation in the diabetic heart: Confronting the maze.

  2011cites this paper
• Myocardial fatty acid metabolism in health and disease.

  2010cites this paper
• Metabolic therapy at the crossroad: how to optimize myocardial substrate utilization?

  2009cites this paper
• Metoprolol improves cardiac function and modulates cardiac metabolism in the streptozotocin-diabetic rat.

  2008cites this paper
• Chronic Activation of Peroxisome Proliferator-Activated Receptor-α with Fenofibrate Prevents Alterations in Cardiac Metabolic Phenotype without Changing the Onset of Decompensation in Pacing-Induced Heart Failure

  2007cites this paper
• Chronic Activation of PPAR α with Fenofibrate Prevents Alterations in Cardiac Metabolic Phenotype without Changing the Onset of Decompensation in Pacing-Induced Heart Failure

  2007cites this paper
• Optimizing Cardiac Fatty Acid and Glucose Metabolism as an Approach to Treating Heart Failure

  2006cites this paper
• Myocardial substrate metabolism in the normal and failing heart.

  2005cites this paper
• Carnitine palmitoyl transferase-I inhibition prevents ventricular remodeling and delays decompensation in pacing-induced heart failure.

  2005cites this paper
• [Metabolism and the hypertrophied heart of the elderly].

  2005cites this paper
• Fatty acid oxidation inhibition with PPARalpha activation (FOXIB/PPARalpha) for normalizing gene expression in heart failure?

  2005cites this paper
• Fatty acid oxidation inhibition with PPARα activation (FOXIB/PPARα) for normalizing gene expression in heart failure?

  2005cites this paper
• Stoffwechsel und hypertrophiertes Altersherz

  2005cites this paper
• Risk Stratification by the “EPA+DHA Level” and the “EPA/AA Ratio”

  2004cites this paper
• Carnitine Palmitoyltransferase-I, a New Target for the Treatment of Heart Failure

  2004cites this paper
• Focus on Anti-Inflammatory and Antiarrhythmogenic Effects of Long-Chain Omega-3 Fatty Acids

  2004cites this paper
• Drug Development Based on Functional Genomics of Overloaded Cardiomyocytes: CPT 1 vs. PPARalpha Effects of Etomoxir

  2003cites this paper
• Influence of Transgenic Expression of Sarcoplasmic Reticulum Ca2+ATPase on Reticular Ca2+ Transport in Rat Hearts

  2003cites this paper
• Therapeutic potential of CPT I inhibitors: cardiac gene transcription as a target

  2002cites this paper
• Funktionelle Genomik des druckbelasteten Kardiozyten: Etomoxir bei Herzinsuffizienz?

  2002cites this paper
• Transgenic overexpression of the sarcoplasmic reticulum Ca2+ ATPase improves reticular Ca2+ handling in normal and diabetic rat hearts

  2002cites this paper
• [Functional genomics of pressure-loaded cardiomyocytes: etomoxir in heart failure?].

  2002cites this paper
• Emerging therapeutic targets in chronic heart failure: Part I

  2002cites this paper